Thank you to our speakers, sponsors, and delegates who joined us at the 7th Obesity & NASH Drug Development Summit!
If you are interested in the 2024 event, please get in touch at info@hansonwade.com
Navigate End-To-End Strategic Updates in NASH & Obesity to Define the Evolving Competitive Landscape in Metabolic Disorders
Returning in September 2024
Welcome to the 7th Obesity & NASH Drug Development 2023 Summit
Eli Lilly’s ‘triple G’ drug retatrutide has galvanized the metabolic field to boost investment in the game-changing obesity drug revolution. With up to 24% weight loss, a new record for the obesity field has been set and the time to get ahead of the curve is now.
In parallel, we’re witnessing history being made with the world’s first approved NASH treatment potentially being right around the corner with Madrigal’s THR β-selective agonist, marking this year a pivotal time for the metabolic field to forever elevate the approach towards drug development and overcome regulatory barriers.
The 7th Obesity & NASH Drug Development Summit Reunited metabolic experts to enable the assessment of the competitive landscape . Participants had the opportunity to:
- better understand the state of blood based, imaging and predictive biomarkers to meet primary endpoints and attain regulatory approval
- explore GLP-1 RAs in a new light with FGF21, GIP, Amylin, glucagon receptors and more to lead to better therapeutic profile
- ascertain a safety profile and successfully demonstrate efficacy in combination therapy to accurately assess multiple mechanisms of action
With 160+ experts from Eli Lilly, Novo Nordisk, Madrigal, Akero, Gilead, Pfizer, AstraZeneca, Gilead, Inventiva, and many more, participants discussed sustainable weight-loss drugs and the route towards the first approval in NASH.
2023 Expert Speaker Faculty:
Mary Haas
Senior Manager, Cardiovascular Metabolic & Skeletal Disease Genetics
Regeneron Pharmaceuticals Inc
Rebecca Taub
Founder, Chief Executive & Medical Officer, President - Research & Development
Madrigal Pharmaceuticals
2023 Attending Companies Included:
What do GLP-1 agonists mean for obesity and NASH treatment?
Tien Lee, CEO of Aardvark Therapeutics shares their insights.